NuGen Announces the Appointment of Liang Lin as Chief Executive Officer
NuGen Medical Devices has appointed Liang Lin as its new Chief Executive Officer. Lin, who joined NuGen's board in September 2024 following Sol-Millennium Medical Group's (SolM) strategic investment, brings extensive experience in the medical device sector. As the founder and CEO of SolM, Lin has demonstrated success in expanding international operations, particularly in North America and Brazil through strategic acquisitions.
Under Lin's leadership, SolM has established offices across Europe and the Middle East, invested in R&D facilities in Asia and Europe, and developed innovative medical devices. Lin replaces Karen Dunlap, who served as Interim CEO and will continue with the company as director and Chief Customer Officer. In his new role, Lin aims to leverage his industry expertise to drive global sales growth and meet anticipated InsuJet™ production demands for 2025.
NuGen Medical Devices ha nominato Liang Lin come nuovo Amministratore Delegato. Lin, che è entrato a far parte del consiglio di NuGen a settembre 2024 a seguito dell'investimento strategico del Sol-Millennium Medical Group (SolM), porta con sé una vasta esperienza nel settore dei dispositivi medici. Come fondatore e CEO di SolM, Lin ha dimostrato successo nell'espandere le operazioni internazionali, in particolare in Nord America e Brasile tramite acquisizioni strategiche.
Sotto la guida di Lin, SolM ha aperto uffici in tutta Europa e Medio Oriente, investito in strutture di R&S in Asia e Europa, e sviluppato dispositivi medici innovativi. Lin sostituisce Karen Dunlap, che ha servito come CEO ad interim e continuerà a lavorare nell'azienda come direttore e Chief Customer Officer. Nel suo nuovo ruolo, Lin punta a sfruttare la sua esperianza nel settore per stimolare la crescita delle vendite globali e soddisfare la domanda prevista di produzione di InsuJet™ per il 2025.
NuGen Medical Devices ha nombrado a Liang Lin como su nuevo Director Ejecutivo. Lin, quien se unió a la junta de NuGen en septiembre de 2024 tras la inversión estratégica del Sol-Millennium Medical Group (SolM), aporta una amplia experiencia en el sector de dispositivos médicos. Como fundador y CEO de SolM, Lin ha demostrado éxito en la expansión de las operaciones internacionales, particularmente en América del Norte y Brasil a través de adquisiciones estratégicas.
Bajo el liderazgo de Lin, SolM ha establecido oficinas en toda Europa y Medio Oriente, ha invertido en instalaciones de I+D en Asia y Europa, y ha desarrollado dispositivos médicos innovadores. Lin reemplaza a Karen Dunlap, quien se desempeñó como CEO interino y continuará con la empresa como directora y Chief Customer Officer. En su nuevo cargo, Lin tiene como objetivo aprovechar su experiencia en la industria para impulsar el crecimiento de las ventas globales y satisfacer la demanda anticipada de producción de InsuJet™ para 2025.
NuGen Medical Devices는 Liang Lin을 새로운 CEO로 임명했습니다. Lin은 2024년 9월 Sol-Millennium Medical Group (SolM)의 전략적 투자에 따라 NuGen 이사회에 합류했으며, 의료 기기 분야에서 폭넓은 경험을 가지고 있습니다. SolM의 창립자이자 CEO인 Lin은 전략적 인수를 통해 북미 및 브라질에서 국제 운영을 확대하는 데 성공을 거두었습니다.
Lin의 리더십 아래 SolM은 유럽과 중동 전역에 사무소를 설치하고 아시아와 유럽에 연구개발(R&D) 시설에 투자하며 혁신적인 의료 기기를 개발했습니다. Lin은 임시 CEO 역할을 했던 Karen Dunlap을 대체하며, Dunlap은 이사이자 Chief Customer Officer로 남아 회사에 계속 기여할 것입니다. 자신의 새로운 역할에서 Lin은 산업 전문성을 활용하여 글로벌 매출 성장을 촉진하고 2025년 InsuJet™ 생산 수요를 충족하는 것을 목표로 하고 있습니다.
NuGen Medical Devices a nommé Liang Lin comme nouveau Président-Directeur Général. Lin, qui a rejoint le conseil d'administration de NuGen en septembre 2024 suite à l'investissement stratégique du Sol-Millennium Medical Group (SolM), possède une vaste expérience dans le secteur des dispositifs médicaux. En tant que fondateur et PDG de SolM, Lin a démontré son succès dans l'expansion des opérations internationales, en particulier en Amérique du Nord et au Brésil grâce à des acquisitions stratégiques.
Sous la direction de Lin, SolM a établi des bureaux à travers l'Europe et le Moyen-Orient, investi dans des installations de R&D en Asie et en Europe, et développé des dispositifs médicaux innovants. Lin remplace Karen Dunlap, qui a exercé la fonction de PDG intérimaire et continuera à travailler au sein de l'entreprise en tant que directrice et Chief Customer Officer. Dans son nouveau rôle, Lin vise à tirer parti de son expertise dans l'industrie pour stimuler la croissance des ventes à l'échelle mondiale et répondre à la demande anticipée de production d'InsuJet™ pour 2025.
NuGen Medical Devices hat Liang Lin zum neuen CEO ernannt. Lin, der im September 2024 dem Vorstand von NuGen nach einer strategischen Investition der Sol-Millennium Medical Group (SolM) beigetreten ist, bringt umfassende Erfahrung im Bereich medizinischer Geräte mit. Als Gründer und CEO von SolM hat Lin erfolgreich internationale Geschäfte ausgeweitet, insbesondere in Nordamerika und Brasilien durch strategische Übernahmen.
Unter Lins Führung hat SolM Büros in ganz Europa und im Nahen Osten etabliert, in F&E-Einrichtungen in Asien und Europa investiert und innovative medizinische Geräte entwickelt. Lin ersetzt Karen Dunlap, die als Interims-CEO fungierte und weiterhin als Direktorin und Chief Customer Officer im Unternehmen bleibt. In seiner neuen Rolle möchte Lin sein Fachwissen nutzen, um das globale Umsatzwachstum voranzutreiben und die erwartete Nachfrage nach InsuJet™-Produktion für 2025 zu erfüllen.
- Strategic appointment of experienced medical device industry leader
- CEO brings proven track record of international market expansion
- Strong R&D and innovation background through SolM leadership
- Existing connection to NuGen through SolM's strategic investment
- None.
Toronto, Ontario--(Newsfile Corp. - January 14, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce the appointment of Mr. Liang Lin as the new Chief Executive Officer of NuGen.
Liang is the founder and CEO of Sol-Millennium Medical Group ("SolM"), an organization committed to transforming the medical device sector through innovative approaches and a strong focus on patient safety. He initiated the SolM project in Shanghai, motivated by a vision to enhance health outcomes for patients globally. His unwavering commitment to innovation has led to the development of advanced medical devices that not only meet but exceed industry standards. Under Liang's dynamic leadership, SolM has made significant strides in expanding its international footprint. The organization has successfully penetrated the North American and Brazilian markets through strategic acquisitions, including Inviro Medical Inc. and Medica Brazil. Additionally, SolM has established offices across Europe and the Middle East, allowing the company to address a diverse range of healthcare needs and adapt to the unique challenges of various healthcare systems. To support its ambitious growth objectives, SolM has invested heavily in research and development, creating state-of-the-art facilities in both Asia and Europe. This commitment to R&D has enabled the company to build a robust pipeline of innovative products poised to make a significant impact on the medical device industry.
Liang will leverage his extensive knowledge and experience in the medical device field to drive innovation and growth at NuGen. His thorough understanding of industry trends, regulatory requirements, and technological advancements will enable the company to navigate the complexities of the market effectively. With his guidance, NuGen is expected to flourish, capitalizing on new opportunities and expanding its product offerings. Liang's strong leadership abilities position him to inspire and energize the team at NuGen, promoting a culture of collaboration and excellence.
Liang joined the Company's board of directors in September 2024 concurrently with the closing of Sol-M's strategic investment in NuGen.
"As NuGen's Chairman, over the past 4 months, I have been actively working with management to further understand InsuJet'sTM production capabilities in order to meet anticipated global demand in 2025. With this challenge, along with the Company being properly capitalized, I am honoured to assume the role of CEO. My goal is to leverage my experience and grow sales worldwide. I am confident that my expertise in the medical device industry will serve us very well and my object will be met," commented Liang Lin, Chairman and CEO of NuGen.
The Company would like to extend its gratitude to Karen Dunlap, NuGen's former Interim Chief Executive Officer, who led the Company through this transition period. Ms. Dunlap will continue to be involved in the Company in her roles as a director and Chief Customer Officer.
About NuGen
NuGen is a leading developer of needle-free devices to administer therapeutics subcutaneously. The Company is marketing and selling its next-generation InsuJet™ needle-free injection system designed to improve the lives of millions of diabetics. InsuJet™ is approved for sale in 42 countries around the world.
For further information, please visit:
Websites: www.insujet.com, and www.nugenmd.com
Instagram: @NuGenMD
Twitter: @NuGenMD
LinkedIn: https://www.linkedin.com/company/nugenmd/
For further information, please contact:
Liang Lin, Chief Executive Officer
+1 (833) 285-2666
llin@nugenmd.com
To arrange a media interview with NuGen, please contact:
Morna Gorman
(416) 553-1732
morna@nugenmd.com
Notice Regarding Forward-Looking Information:
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237155
FAQ
When did Liang Lin become CEO of NuGen Medical Devices (NGMDF)?
What is Liang Lin's background before joining NuGen Medical Devices (NGMDF)?
When did Liang Lin join NuGen's board of directors?
What happened to NuGen's former Interim CEO Karen Dunlap?
What are Liang Lin's primary objectives as new CEO of NuGen (NGMDF)?
